-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Professor Souverain and others reported the following case in the journal AJNR, let's take a look at the medical history
The patient is a 45-year-old man with progressive hemiplegia and a history of
Figure 1-3.
Progressive multifocal leukoencephalopathy
Progressive multifocal leukoencephalopathy (PML) is a subacute demyelination disease that causes focal or multifocal neurological deficits due to JC virus activation, typically in severely immunosuppressed patients, and can lead to immunoreconstructive inflammatory syndrome (IRIS)
Clinical symptoms: no specialities, including headache, seizures, and focal nerve loss
Diagnostic basis: Neuroimaging combined with cerebrospinal fluid polymerase chain reaction (PCR) confirms JC viral DNA
Key points of diagnostic imaging:
single or multiple asymmetric white matter lesions characterized by low T1 and high T2 signals, with limited marginal diffusion visible, which supports the diagnosis of demyelinating lesions;
Most lesions are in the pericerebral white matter and cortex, showing a fan-shaped U-fiber shape;
Occasional cerebellar and brainstem involvement;
Gray matter involvement is uncommon;
The placeholder effect is not obvious;
Occasionally with the edge of the lesion and scattered within the lesion punctate enhancement
Differential diagnosis: lymphoma; New multiple sclerosis appears after the patient receives monoclonal antibodies; Acute disseminated encephalomyelitis
Treatment: it is not clear that HAART is effective
